This comprehensive investor profile synthesizes the operational, strategic, and financial standing of **Gennex Laboratories Limited**, an Indian pharmaceutical entity specializing in the Active Pharmaceutical Ingredient (API) and biotech sectors. ### Core Manufacturing Infrastructure and Strategic Footprint Gennex Laboratories operates a robust manufacturing network designed for multi-product flexibility and high-volume output. The company’s infrastructure is strategically located within India’s primary pharmaceutical hubs. * **Unit I (Main Plant - Telangana):** Located at **Sy.No.133, IDA Bollaram**, this facility serves as the primary multipurpose plant. It features a dedicated production block designed to handle increased tonnages for core APIs. * **Unit II (Subsidiary - Andhra Pradesh):** Operated through **Deccan Remedies Limited** (in which Gennex holds a **51% stake**), this unit is situated at **Plot No. 58A, J.N. Pharma City, Parawada**. It was acquired to bolster the production of intermediates and bulk drugs. * **Future Expansion (Chitoor):** The company has secured land in the **Chitoor District (AP)** for a proposed expansion. The project is currently in the regulatory phase, pending the conversion of land use from agricultural to industrial. ### Diversified Product Portfolio and Therapeutic Reach The company has aggressively expanded its product list between **2023 and 2025**, transitioning from a niche manufacturer to a broad-spectrum API provider. | Therapeutic Category | Key Products | Standards Compliance | | :--- | :--- | :--- | | **Core High-Volume APIs** | **Guaifenesin**, **Methocarbamol**, **Phenazopyridine Hcl** | IP, USP, Ph.Eur, BP | | **Gastrointestinal** | Pantoprazole Sodium, Rabeprazole Sodium, Domperidone Maleate | IP, USP, Ph.Eur, EP | | **Cardiovascular** | Clopidogrel Bisulphate, Telmisartan, Apixaban, Irbesartan | USP, IP, Ph.Eur, IHS | | **CNS / Neurology** | Pregabalin, Escitalopram Oxalate, Sertraline, Oxcarbazepine | IP, USP, Ph.Eur | | **Anti-Fungal/Viral** | Fluconazole, Voriconazole, Lamivudine, Tenofovir | IP, BP, USP, EP | | **Respiratory** | Fexofenadine Hydrochloride, Montelukast Sodium | USP, Ph.Eur, JP, IP | | **Specialty** | Allopurinol (Gout), Minoxidil (Hair loss), Nitazoxanide | USP, EP, IP, IHS | ### Quality Benchmarking and Global Regulatory Compliance To facilitate international trade, Gennex maintains a rigorous compliance framework. Its products are manufactured to meet the pharmacopoeia standards of the **US (USP)**, **Europe (Ph.Eur/EP)**, **UK (BP)**, and **Japan (JP)**. * **Certifications:** Holds **ISO 9001:2015**, **ISO 14001:2015**, and **ISO 45001:2018** (TUV NORD). * **International Access:** Secured **European Union Written Confirmation (EU-WC)** for its core products: **Guaifenesin**, **Methocarbamol**, and **Phenazopyridine Hcl**. * **Domestic Licensing:** Maintains **WHO-GMP** (valid until **July 5, 2026**) and **Form 25** manufacturing licenses (valid until **May 28, 2028**). * **Recent Approvals (2024-2025):** Granted **Form 29 (Test License)** for 10 products including **Atorvastatin Calcium** and **Carvedilol**. New manufacturing permissions were added in 2025 for **Acyclovir**, **Ezetimibe**, and **Moxifloxacin Hydrochloride**. ### Strategic Growth and Capital Allocation The management is executing a multi-pronged strategy to capture outsourcing opportunities from global firms facing patent expirations. * **Inorganic Growth:** The acquisition of the **51% stake** in **Deccan Remedies Limited** included a running pharma plant in **Visakhapatnam** previously owned by Forel Labs. * **R&D Investment:** Plans are underway to establish a dedicated **Research and Development unit** to facilitate the filing of **Drug Master Files (DMFs)** in regulated overseas markets. * **Global Expansion:** The company is exploring the establishment of a **wholly-owned foreign subsidiary** to manage international marketing and manufacturing activities. * **Fundraising and Liquidity:** In **January 2024**, the company raised **₹73,75,00,000** through a preferential equity issue of **5,00,00,000 shares** at **₹14.75**. * **Promoter Commitment:** Between **June and July 2025**, the Promoter Group (**Premier Fiscal Services Private Limited**) converted **1,55,00,000 warrants** into equity, injecting **₹17,14,30,000** into the business. ### Financial Performance and Solvency Metrics Gennex has demonstrated a significant turnaround in profitability and a substantial strengthening of its balance sheet. | Metric (₹ in Crore) | FY 2023-24 | FY 2022-23 | FY 2021-22 | | :--- | :---: | :---: | :---: | | **Total Revenue** | **71.10** | **68.50** | **62.60** | | **EBITDA** | **16.72** | **7.99** | **6.76** | | **Net Profit** | **11.91** | **4.58** | **4.11** | | **Net Block (Fixed Assets)** | **22.28*** | **15.18** | **13.70** | *\*As of March 31, 2025.* **Key Financial Ratios:** * **Net Profit Margin:** Improved from **9.7%** to **20.8%** in the last fiscal year. * **Debt-Equity Ratio:** Drastically reduced from **1.529** to **0.203**, reflecting a shift toward equity-funded growth. * **Current Ratio:** Strengthened to **5.454**, indicating high short-term liquidity. * **Gearing Ratio:** Reduced to **10%** as of March 2024. ### Risk Profile and Governance Oversight While the company is on a growth trajectory, it faces several regulatory and operational hurdles that require active management. * **Audit Qualifications:** Statutory auditors have issued a **Repetitive Qualified Opinion** regarding the inability to reconcile balances for **Trade Receivables, Payables, and Current Assets**. The financial impact of these discrepancies remains "unascertainable." * **Regulatory Penalties:** The company was fined by **BSE Limited** in late 2024 and early 2025 for failing to maintain the required number of **Independent Directors** under SEBI Regulation 17(1)(b). * **Environmental Compliance:** The **Anakapalli** plant must maintain solvent losses below **5%** and provide digital public displays of hazardous waste data to satisfy **APPCB** mandates. * **Operational Risks:** * **Utilization Clause:** Failure to manufacture approved drugs without "reasonable cause" can lead to the **deletion** of those products from the license. * **Market Risk:** Exposure to variable interest rates (Bank 1-year MCLR) and commodity price fluctuations. * **Promoter Pledges:** Shares held by the promoter group are currently **pledged** in favor of **Vidya Tradecon Private Limited**. * **Taxation:** Pending Income Tax appeals involve a potential liability of **₹2.04 crore**.